Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia

J Clin Oncol. 1997 May;15(5):1778-85. doi: 10.1200/JCO.1997.15.5.1778.

Abstract

Purpose: To determine the frequency of the deletions of p15/p16 genes in adult T-cell leukemia (ATL) cells and to evaluate their value in the diagnosis of clinical subtypes of ATL patients and the prediction of their clinical outcome.

Materials and methods: Peripheral-blood samples from 114 patients with ATL were examined by Southern blot analysis. In five chronic-type patients who showed disease progression to acute type, serial samples also were examined.

Results: Among 114 patients, 28 (24.6%) showed the deletions of p15 and/or p16 genes. The results were well correlated with the clinical subtypes. Patients with deleted p15 and/or p16 genes had significantly shorter survival times than the patients in whom both genes were preserved (P < .0001). A similar decline in survival time was observed in the analyses within the same subtypes. In multivariate analysis using the Cox proportional hazard model, the deletions of p15 and/or p16 genes emerged as an independent prognostic indicator. Moreover, three of the five chronic-type patients who progressed to acute type lost the p16 gene alone or both the p15 and p16 genes at their exacerbation phase.

Conclusion: The results suggest the following: (1) that the deletions of p15 and/or p16 genes play a key role in the progression of ATL; and (2) that these deletions are reliable prognostic factors that predict shortened survival times.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Carrier Proteins / genetics*
  • Cell Count
  • Cell Cycle Proteins*
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16
  • Diagnosis, Differential
  • Disease Progression
  • Female
  • Gene Deletion*
  • Genes, Tumor Suppressor*
  • Humans
  • Leukemia, Prolymphocytic, T-Cell / diagnosis
  • Leukemia, Prolymphocytic, T-Cell / genetics*
  • Leukemia, Prolymphocytic, T-Cell / pathology
  • Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • Leukemia-Lymphoma, Adult T-Cell / genetics*
  • Leukemia-Lymphoma, Adult T-Cell / pathology
  • Male
  • Proportional Hazards Models
  • Survival Analysis
  • Tumor Suppressor Proteins*

Substances

  • CDKN2B protein, human
  • Carrier Proteins
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16
  • Tumor Suppressor Proteins